Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 1995;33:19-21; doi:10.1136/dtb.1995.33319
Copyright © 1995 by the BMJ Publishing Group Ltd.

Finasteride and benign prostatic hyperplasia

Relevant BNF sections: 6.4.2, 7.4.1

Finasteride (Proscar - MSD), a type II 5{alpha}-reductase inhibitor, was introduced in 1992 for the medical treatment of men with benign prostatic hyperplasia. The manufacturer claims that finasteride can "halt the progress of the disease and reverse the disease process" and that "one year of therapy with finasteride reversed more than 15 years' growth in prostate volume". We examine the clinical effectiveness of finasteride and assess these claims.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Vallance, P. (1996). Drugs and the fetus. BMJ 312: 1053-1054 [Full Text]